Evaluation and management of angioedema of the head and neck

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 14, Issue 3, 2006, Pages 170-175

  Bas, Murat ^a   Hoffmann, Thomas K ^a   Kojda, Georg ^b,c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Institut fur Pharmakologie und Klinische Pharmakologie   (Germany)

Author keywords

Angioedema; Angiotensin type I receptor blockers; Angiotensin converting enzyme inhibitors; Bradykinin; Kallikrein

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALTEPLASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIALLERGIC AGENT; ANTIINFLAMMATORY AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FLUOXETINE; GLUCOCORTICOID; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KALLIKREIN; KALLIKREIN INHIBITOR; KININ; LARONIDASE; LEPIRUDIN; NORADRENALIN; PREDNISOLONE; RITUXIMAB; TACROLIMUS; TESTOSTERONE; TESTOSTERONE ESTER; TRANEXAMIC ACID; VALSARTAN;

ACUTE DISEASE; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BODY WEIGHT DISORDER; BRONCHOSPASM; BURN; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLD INJURY; COMPREHENSION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; ENDOTRACHEAL INTUBATION; EXPERIENCE; FATALITY; FATIGUE; GASTRITIS; GENE MUTATION; GENETIC DISORDER; GROWTH RETARDATION; HEAD AND NECK DISEASE; HEADACHE; HUMAN; INCIDENCE; INFECTION; LARYNX EDEMA; LIFE; LIVER DYSFUNCTION; MEDIATOR; MEDICAL CARE; MENSTRUAL IRREGULARITY; MOLECULAR MECHANICS; MUSCLE CRAMP; MYALGIA; NAUSEA; OXYGEN THERAPY; PATIENT CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN TARGETING; RECOGNITION; RECURRENT DISEASE; RELIABILITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHOCK; SINUSITIS; SKIN; STANDARD; SUBMUCOSA; THREAT; THROMBOSIS; TISSUE DISTRIBUTION; TONSILLITIS; TRACHEOSTOMY; URTICARIA; VERTIGO; VIRILIZATION; WEIGHT GAIN;

ANGIOEDEMA; ANGIOEDEMA, HEREDITARY; ANTI-INFLAMMATORY AGENTS; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS;

EID: 33744963290     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moo.0000193202.85837.7d     Document Type: Review

References (48)

1. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004; 114:629-637.
2. Shiber JR. Angioedema of the arytenoids. N Engl J Med 2005; 353:e15.
3. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005; 53:373-388.
4. Davis AE III. The pathogenesis of hereditary angioedema. Transfus Apher Sci 2003; 29:195-203.
5. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356:213-217.
6. Gompels MM, Lock PJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379-394.
7. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci 2003; 29:235-238.
8. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71:206-215.
9. Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol 2005; 114:3-9.
10. Goring HD, Bork K, Spath PJ, et al. Hereditary angioedema in the German-speaking region. Hautarzt 1998; 49:114-122.
11. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol 2005; 114:10-16.
12. Karlis V, Glickman RS, Stern R, Kinney L. Hereditary angioedema: case report and review of management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83:462-464.
13. Agostoni A, Marasini B, Cicardi M, et al. Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid. Allergy 1978; 33:216-221.
14. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287:452-454.
15. Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982; 284:2-9.
16. Barbosa J, Seal US, Doe RP. Effects of anabolic steroids on haptoglobin, orosomucoid, plasminogen, fibrinogen, transferrin, ceruloplasmin, alpha-1-antitrypsin, beta-glucuronidase and total serum proteins. J Clin Endocrinol Metab 1971; 33:388-398.
17. Gralnick HR, Rick ME. Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease. N Engl J Med 1983; 308:1393-1395.
18. Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72:294-298.
19. Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80:855-860.
20. Keele DK, Worley JW. Study of an anabolic steroid. Certain effects of oxymetholone on small children. Am J Dis Child 1967; 113:422-430.
21. Smith CS, Harris F. Preliminary experience with danazol in children with precocious puberty. J Int Med Res 1977; 5 (Suppl 3):109-113.
22. Schwartz R. Ambiguous genitalia in a term female infant due to exposure to danazol in utero. Am J Dis Child 1982; 136:474.
23. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353:1066-1067.
24. Fermand JP, Levy Y, Bouscary D, et al. Danazol-induced hepatocellular adenoma. Am J Med 1990; 88:529-530.
25. Warin AP, Greaves MW, Gatecliff M, et al. Treatment of hereditary angiooedema by low dose attenuated androgens: disassociation of clinical response from levels of C1 esterase inhibitor and C4. Br J Dermatol 1980; 103:405-409.
26. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111:315-320.
27. Bas M, Kojda G. Angioedema induced by irbesartan [In German]. Apothekenmagazin 2005; 23:254-255.
28. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
29. Hellebrand MC, Kojda G, Hoffmann TK, Bas M. Angioedema due to ACE inhibitors and AT (1) receptor antagonists. German: Hautarzt; 2005.
30. Bas M, Hoffmann TK, Bier H, Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005; 59:233-238.
31. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356:608-609.
32. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005; 99:6-38.
33. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351:1693-1697.
34. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002; 359:2088-2089.
35. Lefebvre J, Murphey LJ, Hartert TV, et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002; 39:460-464.
36. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 1997; 278:232-233.
37. Auchincloss JH, Streeten DH, Gilbert R, Peppi D. Dyspnea in patients with hyperbradykininism and excessive venous pooling. Am J Med 1986; 81:260-266.
38. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24:599-606.
39. Bas M, Kojda G, Bier H, Hoffmann TK. ACE inhibitor-induced angioedema in the head and neck region. A matter of time? [In German]. HNO 2004; 52:886-890.
40. Tanaka KA, Szlam F, Katori N, et al. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res 2004; 113:333-339.
41. Icatibant. HOE 140, JE 049, JE049. Drugs R D 2005; 6:239-244.
42. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 2001; 111:1729-1731.
43. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002; 25:73-76.
44. Hiyoshi H, Yayama K, Takano M, Okamoto H. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension 2004; 43:1258-1263.
45. Raap U, Liekenbrocker T, Wieczorek D, et al. New therapeutic strategies for the different subtypes of urticaria. Hautarzt 2004; 55:361-366.
46. Zacharisen M, Casper R. Pediatric sinusitis. Immunol Allergy Clin North Am 2005; 25:313-332 (vii).
47. Zacharisen MC, Kelly KJ. Allergic and infectious pediatric sinusitis. Pediatr Ann 1998; 27:759-766.
48. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465-474.